Biocon Biologics Enters into a Exclusive License Agreement with Sandoz for the Commercialization of Ogivri (biosimilar, trastuzumab) and Abevmy (biosimilar, bevacizumab) to Treat Cancer
Shots:
- Under the terms of the agreement, Sandoz received the exclusive right to commercialize and distribute Ogivri, the biosimilar version of Herceptin & Abevmy, the biosimilar version of Avastin, across Australia for the treatment of various cancer indications
- Additionally, Sandoz AG will be held responsible to distribute Biocon’s biosimilar versions of trastuzumab and bevacizumab across Australia for the next 5yrs. Earlier, Ogivri & Abevmy were distributed by another pharmaceutical country across Australia
- Herceptin is approved for the treatment of early-stage breast cancer, and Avastin is approved for the treatment of metastatic colorectal cancer (mCRC)
Ref: Biocon Biologics | Image: Biocon Biologics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
